QurAlis reposted this
I'm excited and honored to cochair this topic alongside Jen at ACT this year, with the support of an incredible group of toxicologists and others working behind the scenes. I look forward to seeing you all in Austin this November!
Oligonucleotides and mRNA therapeutics have rapidly advanced over the last 20 years, leading to an increase in novel targets and delivery mechanisms, each with their own unique challenges. What types of development strategies should be employed? Should a surrogate molecule be used? What types of studies should be conducted? Join co-chairs Xihui Xu and Jen Sisler to explore these challenges and the development strategies to address them in symposium S12 at this year's ACT Annual Meeting, titled "Advances and Challenges in Oligonucleotide and mRNA Therapeutics: New Strategies and Regulatory Perspectives". Link for registration to the Annual meeting: lnkd.in/ek5UQRza